 On March 31, 2017 Cardinal Health announced two new strategic agreements that will enable Cordis, Cardinal Health’s interventional vascular business, to rapidly expand its cardiology product offering in China.These strategic agreements will add new percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, manufactured both in China and internationally, to the Cordis’ portfolio.PTCA balloon catheters play a key role in the treatment of patients undergoing percutaneous coronary intervention (PCI).